MedTrace Logo

MK-2206 in Recurrent Nasopharyngeal Carcinoma

NCT01370070 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-01-13

No results posted yet for this study

Summary

To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG

MK-2206

200mg weekly repeated q 28 days

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Brigette Ma, MD, FRACP · Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01370070 on ClinicalTrials.gov